Alphatec Holdings, Inc.
Case Overview
| Status: | Status: Investigating |
| Company Name: | Company Name: Alphatec Holdings, Inc. |
| Ticker: | Ticker: ATEC |
| Related Attorneys: | Lead Attorneys: Thomas W. Elrod |
| Related Practices: | Related Practices: Securities |
The law firm of Kirby McInerney LLP is investigating potential claims against Alphatec Holdings, Inc. (“Alphatec” or the “Company”) (NASDAQ:ATEC). The investigation concerns whether the Company and/or members of its senior management may have violated federal securities laws or engaged in other unlawful business practices.
On May 5, 2026, Alphatec reported its first quarter 2026 financial results and updated its full-year outlook. Among other things, the Company disclosed total revenue of $192 million for the quarter. Alphatec also disclosed EOS revenue of $14 million for the quarter (EOS is Alphatec’s proprietary imaging and informatics platform for diagnostic and surgical planning applications in spinal surgery). During the Company’s earnings call, management stated that the Company’s first quarter revenue was below its internal expectations, primarily due to a shortfall in EOS sales performance. In addition, Alphatec reduced its full-year 2026 EOS revenue outlook to approximately $77 million, compared to prior guidance of approximately $85 million. During the earnings call, management discussed execution issues related to EOS installations. Among other things, management stated that “installation timing was a challenge in the quarter” and that the Company had “committed to a number of units” that it “did not fulfill.” Management further stated that EOS revenue recognition follows installation. On this news, the price of Alphatec shares declined by $3.24 per share, or approximately 32%, from $10.23 per share on May 5, 2026 to close at $6.99 on May 6, 2026.
On May 5, 2026, Alphatec reported its first quarter 2026 financial results and updated its full-year outlook. Among other things, the Company disclosed total revenue of $192 million for the quarter. Alphatec also disclosed EOS revenue of $14 million for the quarter (EOS is Alphatec’s proprietary imaging and informatics platform for diagnostic and surgical planning applications in spinal surgery). During the Company’s earnings call, management stated that the Company’s first quarter revenue was below its internal expectations, primarily due to a shortfall in EOS sales performance. In addition, Alphatec reduced its full-year 2026 EOS revenue outlook to approximately $77 million, compared to prior guidance of approximately $85 million. During the earnings call, management discussed execution issues related to EOS installations. Among other things, management stated that “installation timing was a challenge in the quarter” and that the Company had “committed to a number of units” that it “did not fulfill.” Management further stated that EOS revenue recognition follows installation. On this news, the price of Alphatec shares declined by $3.24 per share, or approximately 32%, from $10.23 per share on May 5, 2026 to close at $6.99 on May 6, 2026.